Office of the Gene Technology Regulator

Avance Clinical Awarded Frost & Sullivan 2021 Asia-Pacific CRO Best Practices Award for Customer Value Leadership

Retrieved on: 
Tuesday, August 10, 2021
Technology, Vaccine, EMA, Office of the Gene Technology Regulator, OGTR, FDA, OMICS Publishing Group, Accreditation, Government, Frost & Sullivan, Contract research organization, Clinical trial, Drug development, Morale, Growth, Review, GMO, Solution, Patient, Frost, Lead, IND, Research, Medidata Solutions, Efficiency, Cros, CRO, Fine chemical, Medicine, Pharmaceutical industry

ADELAIDE, AUS, Aug 10, 2021 - (ACN Newswire) - Avance Clinical, the largest premium Australian CRO for international biotechs, has been awarded the prestigious Frost & Sullivan 2021 Asia-Pacific CRO Customer Value Leadership Award, the second consecutive Asia-Pacific (APAC) CRO Best Practices Award for the company from Frost & Sullivan.

Key Points: 
  • ADELAIDE, AUS, Aug 10, 2021 - (ACN Newswire) - Avance Clinical, the largest premium Australian CRO for international biotechs, has been awarded the prestigious Frost & Sullivan 2021 Asia-Pacific CRO Customer Value Leadership Award, the second consecutive Asia-Pacific (APAC) CRO Best Practices Award for the company from Frost & Sullivan.
  • This is the second Frost & Sullivan award for Avance Clinical, which has seen rapid growth in the APAC region over the past year.
  • Avance Clinical's CEO Yvonne Lungershausen commended her team of more than 150 clinical trial specialists across Australia and New Zealand.
  • Avance Clinical is a Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award recipient and a 2021 Asia-Pacific CRO Customer Value Leadership Award recipient.

Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand

Retrieved on: 
Thursday, May 6, 2021
Health sciences, Clinical research, Health, Pharmaceutical industry, Life sciences, Clinical pharmacology, Clinical trial, Design of experiments, Clinical, Contract research organization, Office of the Gene Technology Regulator

b'ADELAIDE, AUS, May 7, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023.\nIn Australia, dealings with GMOs in clinical research requires authorisation under the Gene Technology Act 2000.

Key Points: 
  • b'ADELAIDE, AUS, May 7, 2021 - (ACN Newswire) - The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023.\nIn Australia, dealings with GMOs in clinical research requires authorisation under the Gene Technology Act 2000.
  • https://www.surveymonkey.com/r/Australian-Clinical-Trials\nAustralia\'s Avance Clinical has more than 20-years of experience and is now one of Australia\'s leading Contract Research Organizations.
  • Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.\nAvance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.
  • Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups.